FDA starts quick review of Merck’s MET-targeting lung cancer...

Merck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer from the FDA after the US regulator started a priority review of the drug,

Agios up as FDA gives Thermo Fisher glioma test breakthrough...

Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib, its experimental drug for brain cancer.

FDA clears Lilly’s Retevmo for RET-positive lung, thyroid ca...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo.

Lilly keeps ahead of Blueprint with swift FDA review for sel...

Relief for Lilly as drug from $8bn Loxo deal clears pivotal ...

Oncolytics: the dawn of a new era in cancer treatment

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunothera